McNeill Jonathan — SEC insider filings
SEC reporting owner CIK 1824673. 31 insider filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 31 filings on record, filed 2020-09-18 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 37 legs across 20 filings — 275,501 shares, $6,075,253 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 36.
- Largest priced transaction: sale of 54,648 shares @ $26.72 ($1,460,195) in Dyne Therapeutics, Inc., filed 2024-03-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | Chief Business Officer | 27 | — | 34 legs · 250,382 sh · $5,628,342 | 32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | President and COO | 4 | — | 3 legs · 25,119 sh · $446,911 | 4 |
Insider filings — McNeill Jonathan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Sale (S): 731 @ $17.90 · Sale (S): 3,839 @ $16.71 | EDGAR |
| 2026-06-23 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Sale (S): 20,549 @ $17.99 | EDGAR |
| 2025-12-17 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Grant/award (A): 19,507 · Grant/award (A): 6,000 · Grant/award (A): 78,029 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Grant/award (A): 172,836 (derivative) @ $0 | EDGAR |
| 2024-08-20 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 2,400 @ $45.01 · Sale (S): 305 @ $46 | EDGAR |
| 2024-06-11 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 1,823 @ $31.34 | EDGAR |
| 2024-05-17 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 2,279 @ $28.20 · Sale (S): 495 @ $28.59 | EDGAR |
| 2024-04-04 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-03-13 | 4 | Dyne Therapeutics, Inc. (DYN) | Option exercise (M): 86,159 @ $5.54 · Option exercise (M): 3,841 @ $5.54 · Sale (S): 34,663 @ $25.46 · Sale (S): 54,648 @ $26.72 · Sale (S): 689 @ $27.31 · Option exercise (M): 17,825 @ $5.54 · +5 more | EDGAR |
| 2024-03-11 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 2,434 @ $25.85 | EDGAR |
| 2024-03-01 | 4 | Dyne Therapeutics, Inc. (DYN) | Option exercise (M): 4,268 @ $0.73 · Sale (S): 4,268 @ $27.50 · Option exercise (M): 24,260 @ $0.73 · Sale (S): 14,103 @ $28.25 · Sale (S): 8,715 @ $29.06 · Sale (S): 1,442 @ $29.70 · +2 more | EDGAR |
| 2024-01-26 | 4 | Dyne Therapeutics, Inc. (DYN) | Option exercise (M): 20,000 @ $0.73 · Sale (S): 19,822 @ $24.52 · Sale (S): 178 @ $25.14 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 11,900 @ $13.10 · Option exercise (M): 17,991 @ $0.73 · Sale (S): 7,691 @ $18.34 · Sale (S): 10,300 @ $19.03 · Option exercise (M): 2,009 @ $0.73 · Sale (S): 2,009 @ $18.04 · +2 more | EDGAR |
| 2023-12-12 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 1,245 @ $10.72 | EDGAR |
| 2023-11-16 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 96,158 @ $0 · Grant/award (A): 37,445 (derivative) @ $0 | EDGAR |
| 2023-09-20 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 1,261 @ $9.41 | EDGAR |
| 2023-09-13 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 1,266 @ $10.41 | EDGAR |
| 2023-06-14 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 1,000 @ $13 · Sale (S): 1,259 @ $12.43 | EDGAR |
| 2023-03-15 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 1,000 @ $13 · Sale (S): 1,209 @ $13.33 | EDGAR |
| 2023-01-23 | 4 | Dyne Therapeutics, Inc. (DYN) | Option exercise (M): 10,000 @ $0.73 · Sale (S): 10,000 @ $14.03 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2023-01-11 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 30,150 @ $11.57 | EDGAR |
| 2022-12-13 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 40,000 @ $0 · Sale (S): 472 @ $10.87 · Grant/award (A): 63,000 (derivative) @ $0 | EDGAR |
| 2022-09-21 | 4 | Dyne Therapeutics, Inc. (DYN) | Disposition to issuer (D): 1,246 @ $13.70 | EDGAR |
| 2022-09-15 | 4 | Dyne Therapeutics, Inc. (DYN) | Disposition to issuer (D): 494 @ $14.05 | EDGAR |
| 2022-07-06 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 21,666 (derivative) @ $0 | EDGAR |
| 2022-06-15 | 4 | Dyne Therapeutics, Inc. (DYN) | Disposition to issuer (D): 504 @ $4.95 | EDGAR |
| 2022-03-14 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 481 @ $8.73 | EDGAR |
| 2021-12-14 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 25,311 @ $0 · Grant/award (A): 37,967 (derivative) @ $0 | EDGAR |
| 2021-09-22 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 545 @ $15.61 · Sale (S): 729 @ $16.11 | EDGAR |
| 2021-07-13 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2020-09-18 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 17,012 @ $0 · Grant/award (A): 52,787 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1824673 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs